

Supplemental Table S1. Overview of All the Included Studies

| Year | First author | ICI type | ICI name | Cancer type | Study type | Total no. of patients |
|------|--------------------------|-----------|--------------|------------------------------------|-----------------------------|-----------------------|
| 2018 | Fang et al. [1] | Anti-PD-1 | Camrelizumab | Nasopharyngeal carcinoma | Single-arm study | 116 |
| 2019 | Nie et al. [2] | Anti-PD-1 | Camrelizumab | Hodgkin lymphoma | Single-arm study | 86 |
| 2019 | Song et al. [3] | Anti-PD-1 | Camrelizumab | Hodgkin lymphoma | Single-arm study | 75 |
| 2019 | Wei et al. [4] | Anti-PD-1 | Camrelizumab | Non-small cell lung cancer | Single-arm study | 21 |
| 2020 | Lickliter et al. [5] | Anti-PD-1 | Camrelizumab | Advanced solid tumors | Single-arm study | 49 |
| 2020 | Chen et al. [6] | Anti-PD-1 | Camrelizumab | Hepatocellular carcinoma | Observational study | 146 |
| 2020 | Qin et al. [7] | Anti-PD-1 | Camrelizumab | Hepatocellular carcinoma | Single-arm study | 220 |
| 2020 | Huang et al. [8] | Anti-PD-1 | Camrelizumab | Esophageal squamous cell carcinoma | Randomized controlled study | 457 |
| 2020 | Liu et al. [9] | Anti-PD-1 | Camrelizumab | Breast cancer | Single-arm study | 50 |
| 2020 | Yuan et al. [10] | Anti-PD-1 | Camrelizumab | Hepatocellular carcinoma | Observational study | 63 |
| 2021 | Wang et al. [11] | Anti-PD-1 | Camrelizumab | Hodgkin lymphoma | Single-arm study | 50 |
| 2021 | Liu et al. [12] | Anti-PD-1 | Camrelizumab | Hodgkin lymphoma | Single-arm study | 61 |
| 2021 | Mei et al. [13] | Anti-PD-1 | Camrelizumab | Liver cancer | Single-arm study | 28 |
| 2021 | Zhou et al. [14] | Anti-PD-1 | Camrelizumab | Non-small cell lung cancer | Randomized controlled study | 419 |
| 2021 | Xu et al. [15] | Anti-PD-1 | Camrelizumab | Hepatocellular carcinoma | Single-arm study | 190 |
| 2022 | Ren et al. [16] | Anti-PD-1 | Camrelizumab | Non-small cell lung cancer | Randomized controlled study | 390 |
| 2021 | Zhang et al. [17] | Anti-PD-1 | Camrelizumab | Esophageal squamous cell carcinoma | Single-arm study | 20 |
| 2021 | Luo et al. [18] | Anti-PD-1 | Camrelizumab | Esophageal squamous cell carcinoma | Randomized controlled study | 596 |
| 2021 | Yang et al. [19] | Anti-PD-1 | Camrelizumab | Nasopharyngeal carcinoma | Randomized controlled study | 263 |
| 2021 | Sun et al. [20] | Anti-PD-1 | Camrelizumab | Gastric cancer | Single-arm study | 6 |
| 2021 | Lin et al. [21] | Anti-PD-1 | Camrelizumab | Rectal cancer | Single-arm study | 30 |
| 2021 | Wang et al. [22] | Anti-PD-1 | Camrelizumab | Biliary tract cancer | Single-arm study | 22 |
| 2021 | Jiang et al. [23] | Anti-PD-1 | Camrelizumab | Colorectal cancer | Observational study | 16 |
| 2021 | Wei et al. [24] | Anti-PD-1 | Camrelizumab | Hepatocellular carcinoma | Observational study | 48 |
| 2021 | Yu et al. [25] | Anti-PD-1 | Camrelizumab | Biliary tract cancers | Single-arm study | 14 |
| 2021 | Zhou et al. [26] | Anti-PD-1 | Camrelizumab | Colorectal cancer | Observational study | 25 |
| 2022 | Yang et al. [27] | Anti-PD-1 | Camrelizumab | Non-small cell lung cancer | Single-arm study | 146 |
| 2022 | Wu et al. [28] | Anti-PD-1 | Camrelizumab | Hodgkin lymphoma | Single-arm study | 101 |
| 2022 | Xia et al. [29] | Anti-PD-1 | Camrelizumab | Ovarian cancer | Single-arm study | 37 |
| 2020 | Papadopoulos et al. [30] | Anti-PD-1 | Cemiplimab | Advance solid cancer | Single-arm study | 60 |
| 2020 | Rischin et al. [31] | Anti-PD-1 | Cemiplimab | Cutaneous squamous cell carcinoma | Single-arm study | 115 |
| 2020 | Migden et al. [32] | Anti-PD-1 | Cemiplimab | Cutaneous squamous cell carcinoma | Single-arm study | 78 |
| 2021 | Kitano et al. [33] | Anti-PD-1 | Cemiplimab | Advanced malignancies | Single-arm study | 13 |
| 2020 | Rischin et al. [34] | Anti-PD-1 | Cemiplimab | Cervical cancer | Single-arm study | 20 |
| 2021 | Sezer et al. [35] | Anti-PD-1 | Cemiplimab | Non-small cell lung cancer | Randomized controlled study | 710 |
| 2021 | Stratigos et al. [36] | Anti-PD-1 | Cemiplimab | Basal cell carcinoma | Single-arm study | 84 |
| 2021 | Baggi et al. [37] | Anti-PD-1 | Cemiplimab | Cutaneous squamous cell carcinoma | Observational study | 131 |

(Continued to the next page)

Supplemental Table S1. Continued

| Year | First author | ICI type | ICI name | Cancer type | Study type | Total no. of patients |
|------|--------------------------|------------|---------------|-------------------------------------|-----------------------------|-----------------------|
| 2021 | Hoher et al. [38] | Anti-PD-1 | Cemiplimab | Cutaneous squamous cell carcinoma | Observational study | 245 |
| 2021 | Valentin et al. [39] | Anti-PD-1 | Cemiplimab | Cutaneous squamous cell carcinoma | Observational study | 22 |
| 2022 | Gogishvili et al. [40] | Anti-PD-1 | Cemiplimab | Non-small cell lung cancer | Randomized controlled study | 466 |
| 2022 | Tewari et al. [41] | Anti-PD-1 | Cemiplimab | Cervical cancer | Randomized controlled study | 608 |
| 2022 | Lu et al. [42] | Anti-PD-1 | Sintilimab | Non-small cell lung cancer | Randomized controlled study | 444 |
| 2019 | Shi et al. [43] | Anti-PD-1 | Sintilimab | Hodgkin lymphoma | Single-arm study | 96 |
| 2020 | Jiang et al. [44] | Anti-PD-1 | Sintilimab | Gastric/gastroesophageal | Single-arm study | 20 |
| 2020 | Gao et al. [45] | Anti-PD-1 | Sintilimab | Non-small cell lung cancer | Single-arm study | 40 |
| 2021 | Jiang et al. [46] | Anti-PD-1 | Sintilimab | Advance solid cancer | Single-arm study | 207 |
| 2021 | Jiang et al. [47] | Anti-PD-1 | Sintilimab | Non-small cell lung cancer | Single-arm study | 41 |
| 2021 | Tao et al. [48] | Anti-PD-1 | Sintilimab | Extranodal NK/T-cell lymphoma | Single-arm study | 28 |
| 2021 | Ni et al. [49] | Anti-PD-1 | Sintilimab | Non-small cell lung cancer | Single-arm study | 20 |
| 2021 | Duan et al. [50] | Anti-PD-1 | Sintilimab | Esophageal cancer | Single-arm study | 23 |
| 2021 | Lu et al. [51] | Anti-PD-1 | Sintilimab | Renal cell carcinoma | Observational study | 17 |
| 2022 | Huang et al. [52] | Anti-PD-1 | Sintilimab | Malignant tumor | Observational study | 48 |
| 2022 | Xu et al. [53] | Anti-PD-1 | Sintilimab | Esophageal squamous cell carcinoma | Randomized controlled study | 190 |
| 2022 | Shi et al. [54] | Anti-PD-1 | Sintilimab | Squamous non-small cell lung cancer | Randomized controlled study | 290 |
| 2022 | Lu et al. [55] | Anti-PD-1 | Sintilimab | Esophageal squamous cell carcinoma | Randomized controlled study | 659 |
| 2020 | Naing et al. [56] | Anti-PD-1 | Spartalizumab | Solid tumor | Single-arm study | 58 |
| 2021 | Minami et al. [57] | Anti-PD-1 | Spartalizumab | Solid tumor | Single-arm study | 18 |
| 2021 | Yao et al. [58] | Anti-PD-1 | Spartalizumab | Neuroendocrine tumor | Single-arm study | 116 |
| 2019 | Wang et al. [59] | Anti-PD-1 | Toripalimab | Gastric cancer | Single-arm study | 58 |
| 2020 | Yang et al. [60] | Anti-PD-1 | Toripalimab | Solid tumor | Single-arm study | 33 |
| 2020 | Wei et al. [61] | Anti-PD-1 | Toripalimab | Malignant solid tumor | Single-arm study | 25 |
| 2020 | Lu et al. [62] | Anti-PD-1 | Toripalimab | Neuroendocrine tumor | Single-arm study | 40 |
| 2020 | Wang et al. [63] | Anti-PD-1 | Toripalimab | Non-small cell lung cancer | Single-arm study | 41 |
| 2020 | Tang et al. [64] | Anti-PD-1 | Toripalimab | Melanoma | Single-arm study | 127 |
| 2021 | Wang et al. [65] | Anti-PD-1 | Toripalimab | Nasopharyngeal carcinoma | Single-arm study | 190 |
| 2021 | Hua et al. [66] | Anti-PD-1 | Toripalimab | Nasopharyngeal carcinoma | Single-arm study | 25 |
| 2022 | Lian et al. [67] | Anti-PD-1 | Toripalimab | Multiple myeloma | Single-arm study | 145 |
| 2022 | Hu et al. [68] | Anti-PD-1 | Toripalimab | Colon cancer | Single-arm study | 17 |
| 2022 | Wang et al. [69] | Anti-PD-1 | Toripalimab | Esophageal squamous cell carcinoma | Randomized controlled study | 514 |
| 2017 | Peters et al. [70] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Single-arm study | 659 |
| 2017 | Balar et al. [71] | Anti-PD-L1 | Atezolizumab | Urinary tract carcinoma | Single-arm study | 119 |
| 2018 | Petrylak et al. [72] | Anti-PD-L1 | Atezolizumab | Urinary tract carcinoma | Single-arm study | 95 |
| 2018 | Fehrenbacher et al. [73] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 2,075 |

(Continued to the next page)

Supplemental Table S1. Continued

| Year | First author | ICI type | ICI name | Cancer type | Study type | Total no. of patients |
|------|-----------------------------|------------|--------------|--|-----------------------------|-----------------------|
| 2018 | Socinski et al. [74] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 800 |
| 2018 | Pal et al. [75] | Anti-PD-L1 | Atezolizumab | Urinary tract carcinoma | Single-arm study | 218 |
| 2019 | Adams et al. [76] | Anti-PD-L1 | Atezolizumab | Breast cancer (metastatic triple-negative) | Single-arm study | 33 |
| 2019 | West et al. [77] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 723 |
| 2019 | Pujol et al. [78] | Anti-PD-L1 | Atezolizumab | Small cell lung cancer | Randomized controlled study | 73 |
| 2020 | Ikedo et al. [79] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Single-arm study | 17 |
| 2020 | Jotte et al. [80] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 1,021 |
| 2020 | Herbst et al. [81] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 554 |
| 2020 | Lin et al. [82] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Single-arm study | 40 |
| 2020 | Shu et al. [83] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Single-arm study | 30 |
| 2020 | Galsky et al. [84] | Anti-PD-L1 | Atezolizumab | Urinary tract carcinoma | Randomized controlled study | 1,213 |
| 2020 | Emens et al. [85] | Anti-PD-L1 | Atezolizumab | Breast cancer (HER2-positive advanced) | Randomized controlled study | 202 |
| 2020 | Loriot et al. [86] | Anti-PD-L1 | Atezolizumab | Urinary tract carcinoma | Single-arm study | 997 |
| 2020 | Mittendorf et al. [87] | Anti-PD-L1 | Atezolizumab | Breast cancer (TNBC) | Randomized controlled study | 333 |
| 2021 | van der Heijden et al. [88] | Anti-PD-L1 | Atezolizumab | Urothelial carcinoma | Randomized controlled study | 902 |
| 2021 | Emens et al. [89] | Anti-PD-L1 | Atezolizumab | Breast cancer (triple-negative) | Randomized controlled study | 902 |
| 2021 | Bellmunt et al. [90] | Anti-PD-L1 | Atezolizumab | Urinary tract carcinoma | Randomized controlled study | 809 |
| 2021 | Felip et al. [91] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 1,005 |
| 2021 | Nishio et al. [92] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 578 |
| 2021 | Szabados et al. [93] | Anti-PD-L1 | Atezolizumab | Bladder cancer | Single-arm study | 95 |
| 2021 | Moore et al. [94] | Anti-PD-L1 | Atezolizumab | Ovarian cancer | Randomized controlled study | 1,301 |
| 2021 | van den Ende et al. [95] | Anti-PD-L1 | Atezolizumab | Esophageal adenocarcinoma | Single-arm study | 40 |
| 2021 | Miles et al. [96] | Anti-PD-L1 | Atezolizumab | Breast cancer (TNBC) | Randomized controlled study | 651 |
| 2021 | de Azevedo et al. [97] | Anti-PD-L1 | Atezolizumab | Melanoma | Single-arm study | 52 |
| 2021 | Ardizzoni et al. [98] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Single-arm study | 615 |
| 2021 | Furuya et al. [99] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Observational study | 152 |
| 2021 | Liu et al. [100] | Anti-PD-L1 | Atezolizumab | Small cell lung cancer | Randomized controlled study | 403 |
| 2022 | Gianni et al. [101] | Anti-PD-L1 | Atezolizumab | Breast cancer (triple-negative) | Randomized controlled study | 280 |
| 2022 | Tabernero et al. [102] | Anti-PD-L1 | Atezolizumab | Colorectal cancer | Randomized controlled study | 445 |
| 2022 | Kenmotsu et al. [103] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 990 |
| 2022 | Mettu et al. [104] | Anti-PD-L1 | Atezolizumab | Colorectal cancer | Randomized controlled study | 133 |
| 2022 | Pal et al. [105] | Anti-PD-L1 | Atezolizumab | Renal cell carcinoma | Randomized controlled study | 778 |
| 2022 | Rossevold et al. [106] | Anti-PD-L1 | Atezolizumab | Breast cancer (TNBC) | Randomized controlled study | 68 |
| 2022 | Peters et al. [107] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer | Randomized controlled study | 471 |
| 2022 | Huober et al. [108] | Anti-PD-L1 | Atezolizumab | Breast cancer | Randomized controlled study | 454 |
| 2016 | Mizugaki et al. [109] | Anti-PD-L1 | Atezolizumab | Non-small cell lung cancer, melanoma, pancreatic cancer, and thymic cancer | Single-arm study | 6 |
| 2017 | Heery et al. [110] | Anti-PD-L1 | Avelumab | Solid tumor | Single-arm study | 53 |
| 2018 | Dirix et al. [111] | Anti-PD-L1 | Avelumab | Breast cancer | Single-arm study | 168 |

(Continued to the next page)

Supplemental Table S1. Continued

| Year | First author | ICI type | ICI name | Cancer type | Study type | Total no. of patients |
|------|--------------------------------|------------|------------|--|-----------------------------|-----------------------|
| 2019 | Chung et al. [112] | Anti-PD-L1 | Avelumab | Gastric/gastroesophageal cancer | Single-arm study | 90 |
| 2019 | Disis et al. [113] | Anti-PD-L1 | Avelumab | Ovarian cancer | Single-arm study | 125 |
| 2019 | Hassan et al. [114] | Anti-PD-L1 | Avelumab | Mesothelioma | Single-arm study | 53 |
| 2019 | Keilholz et al. [115] | Anti-PD-L1 | Avelumab | Melanoma | Single-arm study | 51 |
| 2019 | Vaishampayan et al. [116] | Anti-PD-L1 | Avelumab | Renal cell carcinoma | Single-arm study | 62 |
| 2019 | Doi et al. [117] | Anti-PD-L1 | Avelumab | Solid tumor | Single-arm study | 40 |
| 2019 | Konstantinopoulos et al. [118] | Anti-PD-L1 | Avelumab | Endometrial cancer | Single-arm study | 31 |
| 2020 | Apolo et al. [119] | Anti-PD-L1 | Avelumab | Urothelial carcinoma | Single-arm study | 249 |
| 2020 | Verschraegen et al. [120] | Anti-PD-L1 | Avelumab | Non-small cell lung cancer | Single-arm study | 156 |
| 2020 | You et al. [121] | Anti-PD-L1 | Avelumab | Gestational trophoblastic tumor | Single-arm study | 15 |
| 2020 | Kim et al. [122] | Anti-PD-L1 | Avelumab | Colorectal cancer | Single-arm study | 33 |
| 2020 | Levy et al. [123] | Anti-PD-L1 | Avelumab | Merkel cell carcinoma | Observational study | 54 |
| 2021 | Guigay et al. [124] | Anti-PD-L1 | Avelumab | Head and neck cancer | Single-arm study | 153 |
| 2021 | Ascierto et al. [125] | Anti-PD-L1 | Avelumab | Merkel cell carcinoma | Single-arm study | 367 |
| 2021 | D'Angelo et al. [126] | Anti-PD-L1 | Avelumab | Merkel cell carcinoma | Single-arm study | 116 |
| 2021 | Park et al. [127] | Anti-PD-L1 | Avelumab | Non-small cell lung cancer | Randomized controlled study | 792 |
| 2021 | Pujade-Lauraine et al. [128] | Anti-PD-L1 | Avelumab | Ovarian cancer | Randomized controlled study | 566 |
| 2021 | Moehler et al. [129] | Anti-PD-L1 | Avelumab | Gastric cancer | Randomized controlled study | 499 |
| 2021 | Monk et al. [130] | Anti-PD-L1 | Avelumab | Ovarian cancer | Randomized controlled study | 998 |
| 2021 | Lee et al. [131] | Anti-PD-L1 | Avelumab | Head and neck cancer | Randomized controlled study | 697 |
| 2021 | Lee et al. [132] | Anti-PD-L1 | Avelumab | Hepatocellular carcinoma | Single-arm study | 30 |
| 2021 | Cowey et al. [133] | Anti-PD-L1 | Avelumab | Merkel cell carcinoma | Observational study | 28 |
| 2022 | Tomita et al. [134] | Anti-PD-L1 | Avelumab | Urothelial carcinoma | Randomized controlled study | 700 |
| 2022 | Zeidan et al. [135] | Anti-PD-L1 | Durvaumab | Myelodysplastic syndromes | Randomized controlled study | 84 |
| 2017 | Powles et al. [136] | Anti-PD-L1 | Durvalumab | Urothelial carcinoma | Single-arm study | 191 |
| 2017 | Antonia et al. [137] | Anti-PD-L1 | Durvalumab | Non-small cell lung cancer | Randomized controlled study | 476 |
| 2018 | Garassino et al. [138] | Anti-PD-L1 | Durvaumab | Non-small cell lung cancer | Single-arm study | 111 |
| 2019 | Siu et al. [139] | Anti-PD-L1 | Durvalumab | Head and neck squamous cell carcinoma | Single-arm study | 67 |
| 2019 | Segal et al. [140] | Anti-PD-L1 | Durvalumab | Head and neck squamous cell carcinoma | Single-arm study | 62 |
| 2019 | Fujiwara et al. [141] | Anti-PD-L1 | Durvaumab | Solid tumor | Single-arm study | 1 |
| 2019 | Zandberg et al. [142] | Anti-PD-L1 | Durvalumab | Head and neck squamous cell carcinoma | Single-arm study | 112 |
| 2019 | O'Reilly et al. [143] | Anti-PD-L1 | Durvalumab | Pancreatic ductal adenocarcinoma | Single-arm study | 33 |
| 2020 | Kelly et al. [144] | Anti-PD-L1 | Durvaumab | Gastric and gastroesophageal junction adenocarcinoma | Single-arm study | 88 |
| 2020 | Ferris et al. [145] | Anti-PD-L1 | Durvalumab | Head and neck squamous cell carcinoma | Randomized controlled study | 489 |
| 2020 | Ferrarotto et al. [146] | Anti-PD-L1 | Durvalumab | Oropharyngeal squamous cell carcinoma | Single-arm study | 29 |
| 2021 | Kelley et al. [147] | Anti-PD-L1 | Durvaumab | | Single-arm study | 104 |

(Continued to the next page)

Supplemental Table S1. Continued

| Year | First author | ICI type | ICI name | Cancer type | Study type | Total no. of patients |
|------|---------------------------|-------------|-----------------------------|---|-----------------------------|-----------------------|
| 2021 | Altorki et al. [148] | Anti-PD-L1 | Durvalumab | Non-small cell lung cancer | Randomized controlled study | 30 |
| 2021 | Antill et al. [149] | Anti-PD-L1 | Durvalumab | Endometrial cancer | Single-arm study | 36 |
| 2021 | Goldman et al. [150] | Anti-PD-L1 | Durvaumab | Small cell lung cancer | Randomized controlled study | 537 |
| 2022 | Park et al. [151] | Anti-PD-L1 | Durvalumab | Esophageal squamous cell carcinoma | Randomized controlled study | 86 |
| 2022 | Sonpavde et al. [152] | Anti-PD-L1 | Durvalumab | Urothelial carcinoma | Single-arm study | 867 |
| 2022 | Park et al. [153] | Anti-PD-L1 | Durvaumab | Small cell lung cancer | Single-arm study | 50 |
| 2020 | Rizvi et al. [154] | Anti-PD-L1 | Durvalumab | Non-small cell lung cancer | Randomized controlled study | 746 |
| 2020 | Powles et al. [155] | Anti-PD-L1 | Durvalumab | Urothelial carcinoma | Randomized controlled study | 690 |
| 2023 | Rosenberg et al. [156] | Anti-PD-L1 | Durvaumab | Urothelial carcinoma | Single-arm study | 76 |
| 2021 | Borghaei et al. [157] | Anti-PD-L1 | Durvalumab | Non-small cell lung cancer | Single-arm study | 68 |
| 2022 | Herbst et al. [158] | Anti-PD-L1 | Durvalumab | Non-small cell lung cancer | Single-arm study | 189 |
| 2009 | Camacho et al. [159] | Anti-CTLA-4 | Tremelimumab | Melanoma | Single-arm study | 89 |
| 2010 | Kirkwood et al. [160] | Anti-CTLA-4 | Tremelimumab | Melanoma | Single-arm study | 251 |
| 2013 | Ribas et al. [161] | Anti-CTLA-4 | Tremelimumab | Melanoma | Randomized controlled study | 655 |
| 2015 | Joshua et al. [162] | Anti-CTLA-4 | Tremelimumab | Melanoma | Single-arm study | 11 |
| 2017 | Maio et al. [163] | Anti-CTLA-4 | Tremelimumab | Mesothelioma | Randomized controlled study | 571 |
| 2017 | Duffy et al. [164] | Anti-CTLA-4 | Tremelimumab | Hepatocellular carcinoma | Single-arm study | 32 |
| 2020 | Sharma et al. [165] | Anti-CTLA-4 | Tremelimumab | Urothelial carcinoma | Single-arm study | 32 |
| 2010 | Chung et al. [166] | Anti-CTLA-4 | Tremelimumab | Colorectal cancer | Single-arm study | 47 |
| 2021 | Campbell et al. [167] | Anti-CTLA-4 | Tremelimumab | Renal cell carcinoma | Single-arm study | 29 |
| 2021 | Edenfield et al. [168] | Combination | Durvalumab and tremelimumab | Rare cancers | Single-arm study | 50 |
| 2020 | Pakkala et al. [169] | Combination | Durvalumab and tremelimumab | Small cell lung cancer | Single-arm study | 9 |
| 2020 | Juergens et al. [170] | Combination | Durvalumab and tremelimumab | Solid tumor | Single-arm study | 136 |
| 2021 | Segal et al. [171] | Combination | Durvalumab and tremelimumab | Colorectal cancer | Single-arm study | 24 |
| 2021 | Sarfaty et al. [172] | Combination | Durvalumab and tremelimumab | Non-urothelial carcinoma of the urinary tract | Single-arm study | 13 |
| 2020 | Kim et al. [173] | Combination | Durvalumab and tremelimumab | Pulmonary sarcomatoid carcinoma | Single-arm study | 18 |
| 2021 | Leighl et al. [174] | Combination | Durvalumab and tremelimumab | Non-small cell lung cancer | Single-arm study | 58 |
| 2022 | Schoenfeld et al. [175] | Combination | Durvalumab and tremelimumab | Non-small cell lung cancer | Single-arm study | 90 |
| 2023 | de Castro Jr et al. [176] | Combination | Durvalumab and tremelimumab | Non-small cell lung cancer | Randomized controlled study | 823 |
| 2022 | Leighl et al. [177] | Combination | Durvalumab and tremelimumab | Non-small cell lung cancer | Single-arm study | 150 |

ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein-1; NK, natural killer cell; PD-L1, programmed death-ligand 1; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; CTLA-4, cytotoxic T lymphocyte-associated antigen 4.